Barely Significant
← all excerpts

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Eur Urol Oncol · 2018 · PMC6692495 · PMID 31158087

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
Unsurprisingly, at the first report of survival data from STAMPEDE, there was not a statistically significant improvement in OS for patients with nonmetastatic PC (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.62–1.47), or evidence of heterogeneity of the treatment effect compared to metastatic PC; a meta-analysis of all randomised controlled trial data in non-metastatic patients showed a trend towards improvement in OS that does not reach statistical significance (HR 0.87, 95% CI 0.69–1.09) [8] .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.